NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405

Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405

1.1 Trifluridine–tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer, that is:

  • in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable, and

  • only when the company provides trifluridine–tipiracil with the discount agreed in the patient access scheme.

 https://www.nice.org.uk/guidance/ta405

Site by Devopa
© Copyright 2019 NHS. All rights reserved.